A new drug claims to reduce the number of eczema breakouts an individual suffers. In a study on the effectiveness of the new drug, 50 subjects were given the new drug and another 50 subjects were given a placebo. At the end of the 6-month study, the group given the new drug reported an average of 1.3 breakouts a month. The group given the placebo reported an average of 4.5 breakouts a month.

The data from the study are rerandomized 10 times. The difference of the means from rerandomization are

1.5, 3.0, 1.8, 1.3, 2.1, 1.9, 2.5, 0.7, 2.1, and 1.9.

What is the most appropriate conclusion about the new drug to draw from this information?

The new drug appears to reduce the number of eczema breakouts since the rerandomized mean differences are close to the mean difference found between the two groups studied.

The new drug does not appear to reduce the number of eczema breakouts since the rerandomized mean differences are close to the mean difference found between the two groups studied.

The new drug does not appear to reduce the number of eczema breakouts since the rerandomized mean differences are considerably greater than the mean difference found between the two groups studied.

The new drug appears to reduce the number of eczema breakouts since the rerandomized mean differences are considerably less than the mean difference found between the two groups studied.